{"organizations": [], "uuid": "54de3c3c8d57fbc2fd7785ac02368091f5fef810", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biocancell-announces-terms-of-25-m/brief-biocancell-announces-terms-of-25-million-funding-round-idUSFWN1PI0TF", "country": "US", "domain_rank": 408, "title": "BRIEF-Biocancell Announces Terms Of $25 Million Funding Round", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T15:10:00.000+02:00", "replies_count": 0, "uuid": "54de3c3c8d57fbc2fd7785ac02368091f5fef810"}, "author": "", "url": "https://www.reuters.com/article/brief-biocancell-announces-terms-of-25-m/brief-biocancell-announces-terms-of-25-million-funding-round-idUSFWN1PI0TF", "ord_in_thread": 0, "title": "BRIEF-Biocancell Announces Terms Of $25 Million Funding Round", "locations": [], "entities": {"persons": [], "locations": [{"name": "nis", "sentiment": "none"}], "organizations": [{"name": "biocancell ltd", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 23, 2018 / 1:11 PM / Updated 8 minutes ago BRIEF-Biocancell Announces Terms Of $25 Million Funding Round Reuters Staff \nJan 23 (Reuters) - Biocancell Ltd: * BIOCANCELL ANNOUNCES TERMS OF $25 MILLION FUNDING ROUND \n* BIOCANCELL LTD - EXECUTED NON-BINDING TERM SHEET FOR PRIVATE EQUITY INVESTMENT IN CO OF ABOUT $25 MILLION; INVESTMENT WILL BE PRICED AT NIS 1.60 PER SHARE​ \n* BIOCANCELL LTD - ‍FUNDRAISING PLANS ARE DESIGNED TO FUND CO‘S INITIATION OF CLINICAL TRIALS OF BC-819 IN EARLY STAGE BLADDER CANCER Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-23T15:10:00.000+02:00", "crawled": "2018-01-23T15:28:33.005+02:00", "highlightTitle": ""}